

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Prescient Therapeutics Limited
<b>ABN</b>	56 006 569 106

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	James Campbell
<b>Date of last notice</b>	25 November 2015

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	-
<b>Date of change</b>	21 December 2016
<b>No. of securities held prior to change</b>	200,000 Unlisted options exercisable at \$0.081 (8.1 cents) per option, expiring on 4 November 2018
<b>Class</b>	Unlisted options exercisable at \$0.1194 (11.94 cents) per option, expiring on 21 December 2019
<b>Number acquired</b>	247,000 unlisted options
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held after change</b>	200,000 Unlisted options exercisable at \$0.081 (8.1 cents) per option, expiring on 4 November 2018 247,000 Unlisted options exercisable at \$0.1194 (11.94 cents) per option, expiring on 21 December 2019
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Grant of unlisted options following shareholder approval provided at the Company's 2016 Annual General Meeting held on 30 November 2016.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Prescient Therapeutics Limited
<b>ABN</b>	56 006 569 106

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Paul Hopper
<b>Date of last notice</b>	9 November 2016

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	<b>Deborah Anne Coleman</b> (a related party of Mr Hopper)  <b>Moreglade Pty Ltd</b> (a controlled entity of Mr Hopper)  <b>Kilinwata Investments Pty Ltd</b> (a controlled entity of Mr Hopper)
<b>Date of change</b>	21 December 2016

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held prior to change</b>	
<b>Paul Edward Alexander Hopper</b>	1,038,137 Fully paid ordinary shares
<b>Deborah Anne Coleman</b> (a related party of Mr Hopper)	2,216,667 Fully paid ordinary shares
<b>Moreglade Pty Ltd</b> (a controlled entity of Mr Hopper)	2,333,334 Fully paid ordinary shares
<b>Kilinwata Investments Pty Ltd</b> (a controlled entity of Mr Hopper)	3,572,778 Fully paid ordinary shares 22,222 Listed Options
<b>Alexandra Jane Hopper</b> (a related party of Mr Hopper)	33,334 Fully paid ordinary shares
<b>Horatia Isabelle Hopper</b> (a related party of Mr Hopper)	33,334 Fully paid ordinary shares
<b>India Lucy Hopper</b> (a related party of Mr Hopper)	33,334 Fully paid ordinary shares
<b>Scarlett Augusta Wiseman Hopper</b> (a related party of Mr Hopper)	33,334 Fully paid ordinary shares
<b>Class</b>	Unlisted options exercisable at \$0.1194 (11.94 cents) per option, expiring on 21 December 2019
<b>Number acquired</b>	1. 247,000 Unlisted options exercisable at \$0.1194 (11.94 cents) per option, expiring on 21 December 2019
<b>Number disposed</b>	2. 133,336 fully paid ordinary shares (refer below – nature of change)
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil
<b>No. of securities held after change</b>	
<b>Paul Edward Alexander Hopper</b>	1,038,137 Fully paid ordinary shares
<b>Deborah Anne Coleman</b> (a related party of Mr Hopper)	2,216,667 Fully paid ordinary shares
<b>Moreglade Pty Ltd</b> (a controlled entity of Mr Hopper)	2,333,334 Fully paid ordinary shares
<b>Kilinwata Investments Pty Ltd</b> (a controlled entity of Mr Hopper)	3,572,778 Fully paid ordinary shares 22,222 Listed Options 247,000 Unlisted options exercisable at \$0.1194 (11.94 cents) per option, expiring on 21 December 2019

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<p><b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<ol style="list-style-type: none"> <li>1. Grant of unlisted options following shareholder approval provided at the Company's 2016 Annual General Meeting held on 30 November 2016.</li> <li>2. Fully paid ordinary shares removed from notice which relate to holdings of Mr Hopper's children, where he does not control the relevant holding.</li> </ol>
---	--

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Prescient Therapeutics Limited
<b>ABN</b>	56 006 569 106

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Steven Engle
<b>Date of last notice</b>	25 November 2015

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	-
<b>Date of change</b>	21 December 2016
<b>No. of securities held prior to change</b>	300,000 Unlisted options exercisable at \$0.081 (8.1 cents) per option, expiring on 4 November 2018
<b>Class</b>	Unlisted options exercisable at \$0.1194 (11.94 cents) per option, expiring on 21 December 2019
<b>Number acquired</b>	370,000 unlisted options
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held after change</b>	300,000 Unlisted options exercisable at \$0.081 (8.1 cents) per option, expiring on 4 November 2018 370,000 Unlisted options exercisable at \$0.1194 (11.94 cents) per option, expiring on 21 December 2019
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Grant of unlisted options following shareholder approval provided at the Company's 2016 Annual General Meeting held on 30 November 2016.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Prescient Therapeutics Limited
<b>ABN</b>	56 006 569 106

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Steven Lee Yatomi-Clarke
<b>Date of last notice</b>	1 July 2016

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	<ol style="list-style-type: none"> <li>1. <b>Arrow Wealth Ltd &lt;Berbay Family A/C&gt;</b> (a controlled entity of Mr Yatomi-Clarke)</li> <li>2. <b>Novetera Pty Ltd &lt;SAYC Super Fund A/C&gt;</b> (a controlled entity of Mr Yatomi-Clarke)</li> <li>3. <b>Alexandra Elizabeth Yatomi-Clarke</b></li> </ol>
<b>Date of change</b>	21 December 2016
<b>No. of securities held prior to change</b>	<ol style="list-style-type: none"> <li>1. 1,245,000 Fully paid ordinary shares 200,000 Unlisted options exercisable at \$0.081 (8.1 cents) per option, expiring on 4 November 2018</li> <li>2. 976,912 Fully paid ordinary shares 70,000 Listed Options</li> <li>3. 172,500 Fully paid ordinary shares</li> </ol>
<b>Class</b>	Fully paid ordinary shares
<b>Number acquired</b>	2,000,000 Fully paid ordinary shares

+ See chapter 19 for defined terms.



**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number disposed</b>	Nil
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$0.094 per share
<b>No. of securities held after change</b>	<ol style="list-style-type: none"> <li>1. 3,245,000 Fully paid ordinary shares 200,000 Unlisted options</li> <li>2. 976,912 Fully paid ordinary shares 70,000 Listed Options</li> <li>3. 172,500 Fully paid ordinary shares</li> </ol>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Grant of loan funded fully paid ordinary shares following shareholder approval provided at the Company's 2016 Annual General Meeting held on 30 November 2016.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

+ See chapter 19 for defined terms.